Physician profile
James A Begun
NPI 1265407563
$3,523.78
in general payments reported to CMS, 2019-2025
16 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $190 · 2021: $125 · 2022: $756 · 2023: $782 · 2024: $770 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.63 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Alcon Vision LLC | $562.85 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Allergan, INC. | $369.06 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $358.38 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $308.61 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $281.26 | 2021-2024 | |
| Biotissue Holdings INC. | $247.59 | 2022-2024 | |
| Oyster Point Pharma, INC. | $203.45 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $134.77 | 2020-2024 | Acuvue |
| Aerie Pharmaceuticals, INC. | $110.81 | 2019 | |
| Glaukos Corporation | $102.73 | 2023 | |
| Dompe US, INC. | $100.10 | 2024 | Oxervate |
| Derma Sciences, INC. | $57.71 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $30.55 | 2022 | |
| Shire North American Group INC | $16.25 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Begun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.